Brad D. Schimel, United States Attorney for the Eastern District of Wisconsin, announced that on December 18, 2025, United States District Judge J.P. Stadtmueller sentenced an advanced practice nurse practitioner from Appleton, Wisconsin, to 16 months’ imprisonment.
The charges stem from the defendant’s unlawful prescribing practices between 2020 and 2024. According to court records, during that period, she issued prescriptions for opioids, including oxycodone, without demonstrating medical necessity. She issued these prescriptions as part of an arrangement with her patients under which the patients agreed to fill the unlawful prescriptions and provide half, or more, of the pills to the defendant for her personal use.
The defendant was aware, while engaging in this conduct, that the individuals to whom she was prescribing did not need the opioids, that they were vulnerable due to mental health issues and addiction, and that they were selling at least some of the pills they retained from the unlawful prescriptions.
In announcing the sentence, Judge Stadtmueller noted the defendant’s serious abuse of a position of trust, the “staggering” volume of prescriptions issued without medical need, and the need to promote deterrence among medical professionals who may be tempted to engage in similar unlawful prescribing practices.
Upon completion of her 16-month prison sentence, the defendant will serve a three-year term of supervised release.
Compliance Perspective
Issue
Healthcare organizations and licensed professionals must ensure that prescribing practices are based on legitimate medical need, adhere to applicable laws and professional standards, and protect individuals receiving care from exploitation or harm. Inappropriate prescribing of controlled substances—particularly when influenced by personal gain or misuse—can place vulnerable individuals at significant risk and expose organizations to serious legal, regulatory, and ethical consequences. Facilities are responsible for establishing effective oversight mechanisms, promoting ethical decision-making, and maintaining systems that detect and prevent improper prescribing and diversion of medications.
Discussion Points
- Review policies and procedures governing prescribing practices, controlled substance management, and professional conduct. Policies should outline expectations for medical necessity, documentation requirements, monitoring of prescribing patterns, and steps for reporting suspected misconduct. Procedures should also define how concerns are escalated and investigated. Periodic review of these policies—potentially with input from an experienced healthcare consultant—can help ensure alignment with current regulations and best practices.
- Ensure that appropriate staff receive education on regulatory expectations, ethical standards, and organizational policies related to prescribing practices and controlled substance oversight. Education should focus on recognizing red flags, understanding documentation and reporting requirements, and reinforcing professional accountability. Med-Net Academy offers the course Red Flags of Fraud, which explains how to identify warning signs of potential fraud by outside contractors, the penalties for failing to detect fraud, proper procedures for reporting suspected violations, and guidance on handling external communications.
- Conduct periodic audits to monitor prescribing activity, documentation, and controlled substance utilization to identify unusual patterns, gaps, or inconsistencies. Audits should inform corrective actions and quality improvement efforts. Engaging an external reviewer or consultant to assist with focused reviews or mock assessments can provide objective insight, strengthen oversight processes, and help identify areas of risk before they escalate into regulatory or enforcement issues.
*This news alert has been prepared by Med-Net Concepts, Inc. for informational purposes only and is not intended to provide legal advice.*